| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Neuraxis, Inc.$7
-0.16 (-2.23%)
Market Cap
91.40 M
EPS
-0.81
P/E Ratio
-
Value Trade
1.29 M
SEC Financials
Q1 2026Dilution Risk
35%Revenue
1.61 M
R&D Expenses
99.57 K
Operating CF
-1.23 M
Total Assets
8.75 M
Total Liabilities
3.00 M
Equity
5.75 M
D/E Ratio
12,345
-10.98 %
Week
0.96 %
1 Month
36.97 %
3 Month
194.02 %
6 Month
17.14 %
5 Year
17.14 %
All Time
Cash Data
Cash Position
7.08 M
Monthly Burn
410.00 K
Runway
16.1 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
66.00 K
52 Week Range
2.20 - 9.33
% held by Insiders
26.01 %
% held by Institutions
19.64 %
Enterprise Value
84.68 M
Total Shares
11.20 M
Short %
8.27 %
Float Shares
6.29 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in NRXS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
NRXS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
NRXS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
NRXS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
NRXS Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
NRXS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
NRXSNeurAxis Reports Record First Quarter 2026 Financial Results Driven by 80% Year Over Year Revenue Growth
NeurAxis reported a record financial performance for Q1 2026, with revenues increasing by 80% year-over-year to $1.6 million. This growth was driven by the effective Category I CPT code for Percutaneous Electrical Nerve Field Stimulation, which improved payor coverage. The company also achieved FDA clearance for treating abdominal pain in children, further expanding its market potential.
Read more →NRXSNeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026
NeurAxis, Inc. will report its first quarter 2026 financial results on May 12, 2026. A conference call is scheduled for the same day at 9:00 am ET to discuss the results. The company focuses on neuromodulation therapies for chronic conditions and has FDA clearance for its IB-Stim technology.
Read more →NRXSNeurAxis Expands Payer Coverage with Four New Medical Policies
NeurAxis, Inc. has announced that four additional health insurers have adopted medical policy coverage for its Percutaneous Electrical Nerve Field Stimulation (PENFS) therapy, IB-Stim, which now has the potential to benefit approximately 1.25 million covered lives. The company emphasizes its commitment to making this non-invasive treatment for functional abdominal pain more accessible and affordable. However, the recent audit report raises concerns about the company's financial stability, noting substantial doubt regarding its ability to continue operations. Despite the risks, NeurAxis continues to see strong momentum in expanding insurance coverage.
Read more →NRXSNeurAxis, Inc. Announces Preferred Stock Dividend
NeurAxis, Inc. has announced a stock dividend on its Series B Preferred Stock, declaring that holders of record will receive common stock based on accrued and unpaid dividends. The dividend is set to be issued on April 28, 2026, with approximately 510,605 shares expected to be distributed. This move signifies NeurAxis's commitment to its shareholders as it continues to focus on developing neuromodulation therapies for chronic conditions.
Read more →NRXSNeurAxis Reports Strong Fourth Quarter and Full Year 2025 Financial Results
NeurAxis, Inc. reported strong financial results for the fourth quarter and full year 2025, with revenues increasing 33% year-over-year to $3.6 million. Key achievements included receiving FDA clearance for abdominal pain treatment and a Category I CPT code assignment for its IB-Stim technology. Despite the revenue growth, the company experienced an increased operating loss attributed to higher sales expenses and a one-time legal settlement. Management highlighted plans for expanding medical policy coverage and scaling adoption of their therapies moving forward.
Read more →NRXSNeurAxis to Host Fourth Quarter and Full Year 2025 Results and Business Update Call on Thursday, March 19, 2026
NeurAxis, Inc. will announce its fourth quarter and full year 2025 financial results on March 19, 2026. A conference call is scheduled for the same day at 9:00 am ET to discuss these results. The company specializes in neuromodulation therapies and has FDA clearance for its IB-Stim technology, aimed at treating chronic conditions.
Read more →NRXSNeurAxis Achieves Major Milestone with AMA Category I CPT Code Now in Effect, Establishing a Permanent Reimbursement Pathway
NeurAxis, Inc. has announced the implementation of a Category I CPT code for its Percutaneous Electrical Nerve Field Stimulation (PENFS) therapy, marking a significant milestone in the company’s commercial strategy. This new coding establishes a permanent reimbursement pathway, facilitating broader acceptance and utilization of the therapy in medical practices. With the CPT code now in effect, NeurAxis expects to enhance patient access to care and improve alignment with payers, ultimately supporting future revenue growth. The company's management is optimistic that this breakthrough will strengthen their business foundation and expand coverage opportunities.
Read more →NRXSNeurAxis Achieves Medical Coverage Policy Milestone, Expanding Access to Approximately 45 million additional Covered Lives
NeurAxis, Inc. has announced a significant medical coverage policy for its IB-Stim device, expanding access to approximately 45 million health plan members. This FDA-cleared neuromodulation therapy targets functional abdominal pain in pediatric patients, addressing a critical unmet need. The company aims to secure additional coverage from major insurers and anticipates revenue growth supported by a new CPT code and clinical guidelines.
Read more →NRXSNeurAxis Secures Veterans Affairs Federal Supply Schedule Contract, Broadening Access to More Patients with Functional Abdominal Pain
NeurAxis, Inc. has secured a Veterans Affairs Federal Supply Schedule contract, effective December 1, 2025, allowing broader access to its IB-Stim device for treating functional abdominal pain. This award positions NeurAxis as a federal contractor, enhancing its commercial pathway into the VA health system. The company anticipates that this development will support sustained commercial momentum as it enters 2026.
Read more →NRXSNeurAxis Announces New Medical Policy Coverage in Michigan, Adding 566,000 Covered Lives
NeurAxis, Inc. has announced new medical policy coverage for its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology in Michigan, impacting around 566,000 lives. This expansion increases the total national coverage to approximately 55 million lives. The IB-Stim device is FDA-cleared for treating functional abdominal pain in pediatric patients, filling a critical gap in available therapies.
Read more →NRXSNeurAxis Reports Strong Third Quarter 2025 Financial Results Driven by a 22% Growth in Revenues
NeurAxis, Inc. reported a 22% increase in revenues for Q3 2025, reaching $811,000. The company anticipates significant growth in 2026 following the introduction of a CPT Category I code for its IB-Stim therapy. Despite a decline in gross margin and increased operating losses, management remains optimistic due to recent FDA clearance for expanded indications.
Read more →NRXSNeurAxis to Host Third Quarter 2025 Results and Business Update Call on Tuesday, November 11, 2025
NeurAxis, Inc. will report its third quarter 2025 financial results on November 11, 2025. A conference call is scheduled for the same day at 9:00 am ET to discuss the results. The company focuses on neuromodulation therapies, including its FDA-cleared IB-Stim™ therapy for adolescents with IBS.
Read more →NRXSNeurAxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia (FD) with associated Nausea Symptoms in the Adult Patient Population
NeurAxis, Inc. has received FDA 510(k) clearance for its PENFS technology to treat functional dyspepsia and associated nausea in patients aged 8 and older. This marks the first FDA approval for a treatment specifically targeting functional dyspepsia in adults. The technology provides a non-surgical option for managing chronic abdominal pain, potentially improving the quality of life for many patients.
Read more →NRXSNeurAxis to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
NeurAxis, Inc. will participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025. The company will host a webcast presentation and one-on-one meetings with investors. NeurAxis focuses on neuromodulation therapies, including its FDA-cleared IB-Stim™ therapy for adolescents with IBS. The event aims to enhance investor engagement and showcase the company's advancements.
Read more →NRXSNeurAxis Reports Strong Second Quarter 2025 Financial Results Driven by a 46% Growth in Revenues
NeurAxis, Inc. reported strong financial results for the second quarter of 2025, with a 46% increase in revenues to $894 thousand compared to the same period last year. The company also achieved important regulatory milestones, including FDA clearance for the treatment of pediatric Functional Dyspepsia and new reimbursement codes. Despite these positive developments, NeurAxis faced a decline in gross margin and maintained a significant operating loss. Management expressed optimism about future growth driven by expanding insurance coverage and continued commercialization efforts.
Read more →NRXSNeurAxis to Host Second Quarter 2025 Results and Business Update Call on Tuesday, August 12, 2025
NeurAxis, Inc. plans to host a conference call on August 12, 2025, to discuss its second quarter 2025 financial results. The call will take place before market opening and will also feature a live webcast. This follows the company's commitment to advancing neuromodulation therapies to treat chronic conditions, including irritable bowel syndrome in adolescents. The company’s IB-Stim™ technology has been FDA cleared for functional abdominal pain associated with IBS.
Read more →NRXSNeurAxis Announces New Medical Policy Coverage with Two Health Insurers, Adding 700,000 Covered Lives
NeurAxis, Inc. announced new medical policy coverage for its IB-Stim therapy, expanding access to approximately 700,000 members in Connecticut and Massachusetts. This brings the total coverage for the Percutaneous Electrical Nerve Field Stimulation (PENFS) technology to around 53 million. The company anticipates further policy decisions from major payers and highlights the importance of the upcoming CPT code activation for improved reimbursement.
Read more →NRXSNeurAxis Achieves Critical Milestone; Secures Key Academic Society Guidelines Recommendation for Treatment of Functional Abdominal Pain (FAP) in IBS
NeurAxis, Inc. has achieved a significant milestone with its IB-Stim technology being incorporated into new clinical practice guidelines for treating Functional Abdominal Pain (FAP) in Irritable Bowel Syndrome (IBS). This recognition is expected to enhance insurance coverage and market adoption, potentially benefiting over 600,000 children in the U.S. The company anticipates substantial growth driven by this endorsement and its recent FDA clearances.
Read more →NRXSNeurAxis to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
NeurAxis, Inc. will participate in the Lytham Partners Spring 2025 Investor Conference via a webcast presentation and one-on-one meetings with investors on May 29, 2025. The company's management will discuss their innovative neuromodulation therapies, including the FDA-cleared IB-Stim™ therapy for functional abdominal pain due to irritable bowel syndrome in adolescents. Following the live event, the webcast presentation will also be available for replay. NeurAxis aims to leverage this opportunity to enhance engagement with the investment community and promote its ongoing clinical trials.
Read more →NRXSNeurAxis Announces Closing of $5.0 Million Registered Direct Offering
NeurAxis, Inc. has announced the closing of a registered direct offering, raising approximately $5 million through the sale of 1,538,461 shares at $3.25 each. This financing comes alongside the recent FDA clearance that expands indications for the company's IB-Stim therapy, which addresses Pediatric Functional Abdominal Pain. The CEO highlighted the importance of these developments for improving pediatric care and the company's balance sheet ahead of implementing a new CPT Category I code in 2026. The offering was executed with assistance from Craig-Hallum Capital Group as the placement agent.
Read more →NRXSNeurAxis Announces $5.0 Million Registered Direct Offering
NeurAxis, Inc. announced a $5.0 million registered direct offering under NYSE American rules, involving the sale of 1,538,461 shares at a price of $3.25 per share. The offering is set to close on or about May 22, 2025, pending customary closing conditions. NeurAxis plans to use the net proceeds from this transaction for working capital and general corporate expenses, reflecting its commitment to growth in neuromodulation therapies. The company emphasizes its focus on addressing chronic conditions in children and adults through its IB-Stim technology, which has FDA clearance for treatment associated with IBS in adolescents.
Read more →NRXSNeurAxis Awarded First Ever FDA Clearance for the Treatment of Pediatric FAP/Functional Dyspepsia (FD) and Associated Nausea Symptoms
NeurAxis, Inc. has announced the FDA 510(k) clearance for its IB-Stim technology, allowing for the treatment of Pediatric Functional Abdominal Pain (FAP) associated with Functional Dyspepsia in patients aged 8 to 21. This marks the first FDA-cleared treatment for Functional Dyspepsia, nearly doubling NeurAxis' total addressable market. The company is poised for a seamless commercial rollout utilizing existing provider relationships and reimbursement structures. This achievement reinforces NeurAxis' leadership in pediatric-focused neuromodulation therapies.
Read more →NRXSNeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues
NeurAxis, Inc. reported strong financial results for the first quarter of 2025, showcasing a 39% increase in revenues to $896 thousand year-over-year. The company expanded its total covered lives significantly, reaching approximately 51 million, and received important FDA clearances for its products catering to a broader patient demographic. However, despite these achievements, the operating loss and net loss increased compared to the previous year, with a noted decline in gross margin. Management emphasized that while progress is commendable, they are still addressing only a small fraction of the total addressable market.
Read more →NRXSNeurAxis to Host First Quarter 2025 Results and Business Update Call on Monday, May 12, 2025
NeurAxis, a medical technology company, will report its financial results for the first quarter of 2025 on May 12, 2025. Along with the results, a conference call will be held at 9:00 AM ET to discuss the findings. The company's IB-Stim therapy is FDA cleared for treating functional abdominal pain associated with irritable bowel syndrome in adolescents. Further clinical trials for additional conditions are in progress.
Read more →NRXSNeurAxis to Present at the Planet MicroCap Showcase: VEGAS in partnership with MicroCapClub on Wednesday, April 23, 2025 & 1x1 Meetings on Thursday, April 24, 2025
NeurAxis, Inc. will present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025, highlighting its neuromodulation therapies. CEO Brian Carico will lead the presentation and a Q&A session following it. The company is focused on addressing chronic conditions through its FDA-cleared IB-Stim™ therapy aimed at adolescents with irritable bowel syndrome. Interested investors can also schedule one-on-one meetings during the event.
Read more →NRXSNeurAxis Reports Strong Fourth Quarter 2024 Financial Results Driven by a 43% Increase in Revenues
NeurAxis, Inc. reported a significant 43% increase in revenues for the fourth quarter of 2024, reaching $761 thousand compared to $531 thousand in the same period last year. The company also improved its operating loss by 10% but still faced a net loss of $1.5 million for the quarter. Key operational highlights include the expansion of insurance coverage for its IB-Stim therapy and new FDA clearances that broaden the therapy's patient base. The company is optimistic about future growth driven by upcoming academic guidelines and recent investments enhancing its financial position.
Read more →NRXSNeurAxis to Host Fourth Quarter and Full Year 2024 Results and Business Update Call on Thursday, March 20, 2025
NeurAxis, Inc. will announce its financial results for the fourth quarter and full fiscal year 2024 on March 20, 2025. A conference call is scheduled for the same day at 9:00 AM ET, where the results will be reviewed. NeurAxis specializes in neuromodulation therapies aimed at treating chronic conditions and has a focus on its IB-Stim therapy, which is FDA cleared for IBS in adolescents. The company also highlights ongoing clinical trials for various unmet healthcare needs.
Read more →NRXSNeurAxis Inc. Issues Letter to Shareholders
NeurAxis Inc. has issued a letter to shareholders outlining its achievements in 2024 and its strategic objectives for 2025. The company highlights significant revenue growth driven by the successful commercialization of its IB-Stim treatment for pediatric irritable bowel syndrome and recent FDA approvals that expand its market reach. NeurAxis aims to sustain growth, manage costs effectively, and strengthen its financial position as it prepares to submit applications for new indications. The increase in insurance coverage for its therapies marks a critical milestone in the company's strategy to enhance accessibility for patients.
Read more →NRXSNeurAxis Inc. Announces Strong Preliminary Unaudited Fourth Quarter 2024 Results; Revenues Increased 50% Year-Over-Year Revenues in 4Q24 increased approximately 50% versus 4Q23 Cash balance as of 12/31/24 was approximate
NeurAxis Inc. reported strong preliminary unaudited revenues for the fourth quarter of 2024, with a 50% increase year-over-year, totaling around $800,000. The company achieved a full-year revenue of approximately $2.7 million, marking an 11% growth from the previous year. Key factors contributing to this success include expanded insurance coverage and the FDA clearance for its IB-Stim technology, which is now indicated for a broader age range. NeurAxis is confident in continuing robust growth into 2025, bolstered by new product launches and a strengthened cash balance.
Read more →NRXSNeurAxis Inc. to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
NeurAxis, Inc. announced that CEO Brian Carrico will present at the virtual Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025. The presentation is scheduled for 2:30 PM Eastern Time, with a replay available online. NeurAxis focuses on neuromodulation therapies targeting chronic conditions, emphasizing the significance of its proprietary IB-Stim™ technology, which is FDA-cleared for treating IBS in adolescents. The company invites interested investors for 1x1 meetings following the event.
Read more →NRXSNeurAxis Inc. Announces FDA 510(k) Clearance of RED for Testing and Evaluation of Patients with Chronic Constipation
NeurAxis Inc. has received FDA 510(k) clearance for its Rectal Expulsion Device (RED), which is designed to aid in testing and evaluating patients with chronic constipation caused by pelvic floor dyssynergia. The company plans a soft launch of the RED in Q1 2025, with full commercialization expected by Q2 2025. NeurAxis anticipates that this device will be covered by Medicare and most commercial insurers, and it aims to tap into a total addressable market of approximately $1.5 billion. The clearance marks a significant step in the company's growth strategy within the gastroenterology sector.
Read more →NRXSNeurAxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Increase in Revenues Conference call will be held today, Tuesday, November 12 at 9:00 am ET Carmel, Ind.
NeurAxis, Inc. reported a substantial 40% increase in revenues for the third quarter of 2024, reaching $667 thousand. The company's IB-Stim product experienced a 50% rise in unit sales, coinciding with expanded insurance coverage affecting approximately 35 million lives. Recent milestones include a new FDA 510(K) clearance for younger patients and the establishment of a Category I code by the AMA. Despite these successes, the company continues to handle short-term debt and operational costs associated with its public status.
Read more →NRXSNeurAxis to Host Third Quarter 2024 Results and Business Update Call on Tuesday, November 12, 2024
NeurAxis, Inc. is scheduled to announce its third quarter financial results for 2024 on November 12, 2024. The company will host a conference call at 9:00 am ET to discuss these results, which will be accessible via live webcast. Additionally, NeurAxis is committed to advancing its proprietary IB-Stim™ therapy for treating chronic conditions. The announcement highlights the company’s transparency and is poised to engage investors and stakeholders effectively.
Read more →NRXSNeurAxis Receives New FDA 510(K) Clearance for IB-Stim, Expanding its Addressable Market
NeurAxis, Inc. has announced the receipt of a new FDA 510(k) clearance for its IB-Stim Nonimplanted Nerve Stimulator, designed for functional abdominal pain relief. This clearance expands the market for IB-Stim by approximately 75%, and it allows the use of up to four devices per patient. The company attributes this achievement to robust research backing its PENFS technology and expects increased revenue growth as a result. There are no FDA-approved drug therapies for children with abdominal pain related to gut-brain interaction, emphasizing the significance of this device.
Read more →NRXSNeurAxis Announces New CPT Category I Code for Percutaneous Electrical Nerve Field Stimulation
NeurAxis, Inc. has announced that the American Medical Association has established a new CPT Category I code for its Percutaneous Electrical Nerve Field Stimulation (PENFS) procedures, effective January 1, 2026. The company's IB-Stim device is FDA-cleared for treating functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents aged 11-18. This new coding recognition is expected to enhance patient access and awareness of FDA-cleared treatment options for IBS. NeurAxis is focused on advancing neuromodulation therapies for chronic conditions in children and adults.
Read more →NRXSNeurAxis to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
NeurAxis, Inc. will participate in the Lytham Partners Fall 2024 Investor Conference, scheduled for October 1, 2024. The event will include a webcasted presentation and opportunities for one-on-one meetings with investors. NeurAxis focuses on neuromodulation therapies for chronic conditions, and its IB-Stim™ therapy is FDA cleared for treating functional abdominal pain related to IBS in adolescents aged 11-18. The conference will be held virtually, allowing broader access for investors.
Read more →NRXSNeurAxis Announces Geisinger Health Plan Medical Policy Coverage for PENFS, Effective September 15 2024
NeurAxis, Inc. has announced that the Geisinger Health Plan will provide medical policy coverage for its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, effective September 15, 2024. This move increases the total number of lives covered by PENFS to around 24 million, enhancing access to this treatment for chronic abdominal pain in adolescents. NeurAxis's proprietary IB-Stim device is FDA-cleared for use in patients aged 11-18, addressing a gap in available therapies for irritable bowel syndrome. The company aims to secure coverage for at least 50 million lives by the end of 2024, which could lead to significant revenue growth.
Read more →NRXSNeurAxis Announces BCBS of Vermont Medical Policy Coverage for PENFS, effective October 1st 2024
NeurAxis, Inc. has announced that medical policy coverage for its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology is now available for Blue Cross Blue Shield members in Vermont, effective October 1, 2024. This decision expands the total number of people eligible for coverage to around 23 million. The FDA-cleared IB-Stim therapy addresses functional abdominal pain associated with irritable bowel syndrome in adolescents. The company aims to secure coverage for at least 50 million lives by the end of 2024, anticipating a significant revenue increase in late 2024 and early 2025.
Read more →NRXSNeurAxis Reports Second Quarter 2024 Financial Results Conference call will be held today, Friday, August 9 at 9:00 am ET Carmel, Ind.
NeurAxis, Inc. reported its financial results for the second quarter of 2024, reflecting a revenue decline of 5.3% year-over-year. Despite this dip, the company announced significant expansions in insurance coverage, which could benefit over 35 million lives. NeurAxis is also progressing with FDA submissions for new products, including an innovative rectal device expected to gain clearance later in 2024. Additionally, strong clinical results for its IB-Stim therapy have been reported, demonstrating its effectiveness in treating pediatric patients with abdominal pain.
Read more →NRXSNeurAxis to Host Second Quarter 2024 Results and Business Update Call on Friday, August 9, 2024
NeurAxis, Inc. will announce its financial results for the second quarter of 2024 on August 9, 2024, before the market opens. A conference call will follow on the same day, allowing for questions from interested parties. The company focuses on neuromodulation therapies for chronic conditions and has made progress with its IB-Stim therapy, which is FDA cleared for treating IBS in adolescents. Investors can participate in the call through registration or via a live webcast.
Read more →NRXSNeurAxis Announces New Submission to the FDA for the Expansion of its IB-Stim Label; Provides Compliance with NYSE Guidelines on Audit Disclosure
NeurAxis, Inc. has submitted a request to the FDA to expand the label for its IB-Stim therapy to include patients aged 8-21. The proposed expansion could facilitate treatment for a larger population and allow prescriptions for four devices over consecutive weeks. The company is also complying with NYSE guidelines regarding audit disclosures. While the audit opinion acknowledges concerns about continuing operations, NeurAxis has secured significant financing to enhance its financial standing and operational capabilities.
Read more →NRXSNeurAxis Reports First Quarter 2024 Financial Results
NeurAxis, Inc. reported its first-quarter 2024 financial results, highlighting a substantial expansion in total covered lives to approximately 22.5 million. The company presented promising clinical data demonstrating significant pain improvement in pediatric patients using its IB-Stim technology. However, NeurAxis faced challenges with a 19.7% revenue decline compared to the prior year and an increased operating loss. Despite these setbacks, management remains optimistic about future growth, supported by expanding insurance coverage and new product launches anticipated in late 2024.
Read more →NRXSNeurAxis to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
NeurAxis, Inc. is set to participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024. The company will host a webcasted presentation and engage in one-on-one meetings with investors. This event highlights NeurAxis' focus on commercializing its neuromodulation therapies aimed at chronic conditions. The company's IB-Stim™ therapy has received FDA clearance for treating functional abdominal pain in adolescents with IBS.
Read more →NRXSNeurAxis Announces New Medical Policy Coverage For Nearly Six Million Lives in Florida
NeurAxis, Inc. announced the expansion of medical policy coverage for its IB-Stim technology, now available through a Blue Cross Blue Shield licensee in Florida, benefiting nearly 6 million members. This non-surgical device targets functional abdominal pain in adolescents with irritable bowel syndrome (IBS). The company's CEO expressed excitement about the growth potential and the increase in market adoption for IB-Stim, highlighting the positive reception from children's hospitals in the region. NeurAxis is also advancing clinical trials for its technology addressing various conditions.
Read more →NRXSNeurAxis to Host First Quarter 2024 Results and Business Update Call on Wednesday, May 22, 2024
NeurAxis, Inc. is set to report its financial results for the first quarter of 2024 on May 22, 2024. The company will hold a conference call that same day to discuss these results, which will come after the expected filing of their Form 10-Q. NeurAxis continues to focus on its IB-Stim™ therapy for chronic pain conditions and is committed to advancing clinical trials for various unmet healthcare needs.
Read more →NRXSNeurAxis Announces New Medical Policy Coverage in North Dakota
NeurAxis, Inc. announced the publication of medical policy coverage for its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, set to take effect on May 6, 2024, with a Blue Cross Blue Shield licensee in North Dakota. This coverage will provide access to the IB-Stim™ device for over 310,000 insured individuals in the region, expanding the total patient population for the therapy to approximately 16.5 million. The IB-Stim™ device is aimed at addressing functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents aged 11 to 18, filling a significant gap in pediatric treatment options.
Read more →NRXSNeurAxis Reports Fourth Quarter and Fiscal Year 2023 Financial Results Carmel, Ind.
NeurAxis, Inc. reported its fourth quarter and 2023 fiscal year financial results highlighting significant advancements in insurance coverage for its neuromodulation treatments, particularly for pediatric patients. The company secured coverage for over 16 million lives, an increase from 4 million a year ago, evidencing its growing market presence. Notably, their IB-Stim therapy displayed substantial improvements in abdominal pain for treated patients. However, NeurAxis faced a revenue decline of 8.4% year-over-year due to fewer shipments amid reimbursement process challenges. Additionally, their operational costs have increased, signaling the financial complexities they are managing during expansion.
Read more →NRXSNeurAxis to Host Fourth Quarter and Full Year 2023 Results and Business Update Call on Tuesday, April 9, 2024
NeurAxis, Inc. will report its financial results for Q4 and FY 2023 on April 9, 2024, followed by a conference call at 4:30 pm ET. The company has filed a Form NT 10-K indicating a delay in submitting its Form 10-K, primarily due to issues related to its recent IPO. The firm remains focused on developing neuromodulation therapies for chronic conditions, specifically their IB-Stim™ tech for treating IBS in adolescents.
Read more →NRXSNeurAxis Announces IB-Stim Results from a Large, Pediatric, Multi-Center Registry
NeurAxis, Inc. announced positive results from a multicenter registry study on its IB-Stim therapy for pediatric disorders of gut-brain interaction. The research involved 292 patients, showcasing significant improvements in gastrointestinal symptoms after just four weeks of treatment. With a high percentage of participants having previously failed medication therapies, the findings indicate the potential effectiveness of IB-Stim in challenging cases. NeurAxis aims to commercialize the treatment, furthering its strategy to enhance acceptability and revenue.
Read more →NRXSNeurAxis Announces Highmark BCBS Policy Coverage
NeurAxis, Inc. has secured policy coverage from Highmark Blue Cross Blue Shield, benefiting around seven million lives effective April 8, 2024. This development increases NeurAxis's total covered lives to approximately 16.25 million. The company is focused on expanding its commercial strategy and aims to garner favorable responses from payers nationally for its IB-Stim therapy, which is aimed at treating functional abdominal pain associated with IBS in adolescents.
Read more →NRXSNeurAxis Announces Blue Cross and Blue Shield of Kansas City Policy Coverage
NeurAxis, Inc. has announced that Blue Cross and Blue Shield of Kansas City (BCBSKC) will provide policy coverage for its neuromodulation therapies, affecting approximately one million lives in the Kansas City area. This expansion increases the total covered lives to about 9.25 million for NeurAxis. The company aims to drive market adoption of its IB-Stim therapy, which is FDA cleared for treating functional abdominal pain associated with irritable bowel syndrome in adolescents. Future positive payer responses on a national level are anticipated as more clinical data is published.
Read more →NRXSNeurAxis to Present at Oppenheimer 34th Annual Healthcare MedTech & Services Conference
NeurAxis, Inc. announced its participation in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference, with a presentation scheduled for March 12, 2024. President and CEO Brian Carrico and Chief Medical Officer Dr. Adrian Miranda will represent the company at this event. NeurAxis focuses on neuromodulation therapies for chronic conditions in both children and adults, and the company is actively promoting its FDA-cleared IB-Stim™ therapy, which addresses abdominal pain linked to irritable bowel syndrome. The conference presents an opportunity for NeurAxis to engage with investors and promote its advancements in the medical technology field.
Read more →NRXSNeurAxis Appoints Timothy Henrichs as Chief Financial Officer
NeurAxis, Inc. has appointed Timothy Henrichs as its new Chief Financial Officer, effective February 5, 2024. Henrichs brings over 20 years of experience in financial leadership, including roles at Renovo Home Partners and Follett Corporation. His appointment marks a significant step in the company's strategic efforts to advance commercialization of its neuromodulation therapies, particularly the IB-Stim technology. NeurAxis aims to enhance patient outcomes in disorders related to gut-brain interaction with its FDA-cleared devices.
Read more →NRXSNeurAxis, Inc. Issues Letter to Shareholders from Brian Carrico, President and Chief Executive Officer
NeurAxis, Inc. has issued a letter to shareholders outlining the company's achievements over the past four months and future projections for 2024. The company's robust portfolio of research publications has led to broad insurance policy coverage, driving an expected increase in revenues. NeurAxis plans to market new products targeting Functional Dyspepsia and chronic constipation, both estimated to have $2B market opportunities. The company is on track to exceed its goal of reaching 75M covered lives by the end of 2024.
Read more →NRXSNeurAxis Reports Third Quarter 2023 Financial Results
NeurAxis, Inc. reported its third quarter financial results, revealing a 23% drop in revenue year-over-year. The company highlighted positive findings from a study on its IB-Stim™ therapy, indicating significant improvements in patients with abdominal pain disorders. Despite these clinical advancements, NeurAxis faced challenges with increased net losses and heightened operational costs. Additionally, the company announced new policy coverage, expanding access to its therapies and an exclusive licensing agreement with the University of Michigan for a new device.
Read more →NRXSNeurAxis Announces CareFirst BCBS Policy Coverage
NeurAxis, Inc. has announced that it has received policy coverage from CareFirst Blue Cross Blue Shield for its neuromodulation therapy IB-Stim™ in the mid-Atlantic region. This new coverage impacts approximately 3.5 million lives and increases the company's total covered lives to 8.25 million. NeurAxis's CEO emphasized the importance of leveraging clinical evidence to drive market adoption of their technology. There are ongoing efforts to seek additional payer responses on a national level.
Read more →NRXSNeurAxis Secures $3 Million Financing Carmel, Ind.
NeurAxis, Inc. has announced a successful $3 million financing through a preferred stock offering to enhance its commercialization efforts in neuromodulation therapies. This funding will primarily be used to bolster sales and marketing resources, particularly for its IB-Stim technology and the upcoming rectal expulsion device (RED). The company is actively engaged with payors to expand coverage and is in discussion with the FDA regarding additional indications and the clearance pathway for RED, targeting commercialization in 2024. NeurAxis continues to conduct clinical trials to address significant healthcare needs in pediatric and adult populations.
Read more →NRXSNeurAxis Secures $3 Million Financing
NeurAxis, Inc. has announced the successful acquisition of $3 million in financing through a preferred stock offering, priced at $2.38 per share. This funding will primarily support the company's sales and marketing efforts, enabling further penetration of their neuromodulation therapies. CEO Brian Carrico emphasized the company's commitment to engaging with payors for increased coverage and working with the FDA on their product pathways. NeurAxis aims to commercialize its innovative rectal expulsion device by 2024, along with generating meaningful revenues.
Read more →NRXSNeurAxis Signs Exclusive Option Agreement with University of Michigan for Innovative Gastrointestinal Device
NeurAxis, Inc. has announced an exclusive option agreement with the University of Michigan to license its rectal expulsion device (RED), designed to enhance anorectal function testing. This agreement leverages the significant market potential for RED, which is aligned with NeurAxis' focus on addressing chronic gastrointestinal conditions. The company plans to submit RED for FDA clearance in hopes of commercializing the device in 2024, anticipating meaningful revenues beginning that year.
Read more →NRXSNeurAxis Announces Results of Comparative Study of IB-Stim™ and Standard Medical Therapy in Adolescents with Functional Abdominal Pain Disorders
NeurAxis, Inc. announced positive results from a comparative study of its IB-Stim™ therapy against standard medications for adolescents with functional abdominal pain disorders (FAPD). The study revealed that IB-Stim™ was effective in reducing abdominal pain and improving functional disability compared to baseline measures. In a direct comparison, IB-Stim™ proved more effective than cyproheptadine and was on par with amitriptyline, with the added benefit of fewer side effects. These findings suggest that IB-Stim™ could serve as a valuable non-pharmacologic alternative for treating FAPD in adolescents.
Read more →NRXSNeurAxis Reports Second Quarter 2023 Financial Results Carmel, Ind.
NeurAxis, Inc. announced its financial results for the second quarter of 2023, showing a net loss of $2,235.6 thousand compared to a loss of $1,516.5 thousand in the same period last year. The company's net sales decreased by 5% year-over-year, primarily attributed to changing order patterns from major customers. Despite these financial challenges, NeurAxis is optimistic about its progress, including the publication of clinical evidence supporting its IB-Stim therapy aimed at treating abdominal pain disorders. The company aims to increase its body of clinical research to broaden payor coverage and facilitate the therapy's adoption.
Read more →NRXSNeurAxis to Present at the Gilmartin Group Emerging Growth Showcase
NeurAxis, Inc. will present at the Gilmartin Group Emerging Growth Showcase on September 21, 2023. CEO Brian Carrico and CMO Dr. Adrian Miranda will lead the presentation, focusing on their neuromodulation therapies. NeurAxis specializes in treatments for chronic conditions, including their FDA-cleared IB-Stim™ technology for adolescents experiencing abdominal pain related to IBS. The event will be accessible via a live webcast on their website, with a replay available afterward.
Read more →NRXSNeurAxis Announces Publication of Prospective Study Showing IB-Stim™ Improves Quality of Life of Adolescents with IBS
NeurAxis, Inc. announced the publication of a prospective study demonstrating the effectiveness of its IB-Stim™ therapy in improving the quality of life for adolescents suffering from functional abdominal pain disorders. The randomized trial involved 31 patients aged 11 – 18 years, showing significant reductions in abdominal pain and anxiety after 4 weeks of treatment. Parents also reported notable improvements in their children's quality of life. This publication marks the 10th peer-reviewed paper on NeurAxis's PENFS technology, furthering its goal to establish IB-Stim as the standard treatment for these conditions.
Read more →NRXSNeurAxis Highlights Pediatric Post-Concussion Clinical Study
NeurAxis, Inc. has announced an ongoing clinical study evaluating the efficacy of its IB-Stim™ therapy for children suffering from post-concussion syndrome. This randomized, double-blind, placebo-controlled trial aims to enroll up to 100 patients and will assess improvements through validated measures. The company is optimistic about the potential of IB-Stim™ as a viable treatment option, especially considering the inadequacy of current medications. NeurAxis is also committed to expanding its technology's indications with the support of the FDA.
Read more →NRXSNeurAxis Highlights Strength of its Board of Directors
NeurAxis, Inc. recently emphasized the strengths of its Board of Directors, highlighting key members' relevant experience in medical device commercialization, insurance, and finance. CEO Brian Carrico expressed enthusiasm about the board's capabilities as the company advances its IB Stim Therapy™. The diverse backgrounds of directors, including leadership roles in established healthcare companies, are expected to contribute positively to NeurAxis's mission in neuromodulation therapies.
Read more →NRXSNeurAxis Highlights Two Independent Studies Showing Benefits of IB-Stim in Adolescents Involving the Gut Microbiome
NeurAxis, Inc. highlighted two independent studies demonstrating the effectiveness of IB-Stim therapy in improving symptoms of irritable bowel syndrome (IBS) among adolescents. The studies indicate that the therapy may also influence the gut microbiome, leading to better patient outcomes. Significant reductions in abdominal pain and functional disability were reported post-treatment. The findings suggest a relationship between specific bacterial species and treatment response, underscoring the potential role of the gut-brain axis in addressing pediatric IBS.
Read more →NRXSNeurAxis Announces Over $8 Million in IB-Stim™ Revenue
NeurAxis, Inc. has reported generating over $8 million in revenue following the commercial launch of its IB-Stim™ technology. This proprietary neuromodulation therapy is FDA cleared for treating functional abdominal pain and irritable bowel syndrome in pediatric patients. The company is also engaged in clinical trials for four other pediatric indications. CEO Brian Carrico expressed optimism about the therapy's adoption, fueled by positive clinical data and increasing support from health insurance payors.
Read more →NRXSNeurAxis Announces Positive University of Michigan IB-Stim™ Cost Effectiveness Study at ANMS 2023
NeurAxis, Inc. announced a positive cost-effectiveness study of its IB-Stim™ therapy for irritable bowel syndrome (IBS) in adolescents at the ANMS Annual Meeting. Conducted by the University of Michigan, the study highlighted significant potential savings for both insurers and families, with good treatment outcomes in terms of healthy days. The findings support the clinical adoption of IB-Stim™, emphasizing its economic value alongside its safety and efficacy for treating IBS in children. NeurAxis aims to leverage this evidence for broader acceptance within the medical community.
Read more →NRXSNeurAxis Highlights Current Commercial Insurance Coverage with BCBS Massachusetts, BCBS South Carolina, BCBS Nebraska, and Quartz Wisconsin
NeurAxis, Inc. has announced expanded commercial insurance coverage for its IB-Stim therapy, now covering approximately 4.75 million lives through partnerships with BCBS Massachusetts, South Carolina, Nebraska, and Quartz Wisconsin. The company aims to leverage this coverage to scale operations and remove barriers for hospitals needing prior authorizations. NeurAxis emphasizes the large unmet medical needs in both pediatrics and adults, with a market opportunity of approximately $30 billion combined. The CEO expresses confidence in growing clinical evidence to further support IB-Stim adoption as standard care.
Read more →NRXSNeurAxis Announces Pricing of Initial Public Offering Carmel, IN
NeurAxis, Inc. has announced the pricing of its initial public offering, setting the price at $6.00 per share for 1,098,667 shares. The offering is expected to generate gross proceeds of approximately $6.59 million. Trading on The NYSE American under the ticker 'NRXS' is anticipated to commence on August 9, 2023, with the offering set to close on August 11, 2023, pending customary closing conditions. Proceeds will be utilized for various company activities including R&D and sales initiatives.
Read more →Competitive Position
How NRXS ranks across every disease it competes inCompetitive Position is a premium feature
See how NRXS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial